Traditional urological concerns, such as bladder instability,
bladder cancer,
prostate cancer and incontinence, were focused upon. In addition, significant attention was paid to
erectile dysfunction, with varied developments in the field.
Capsaicin was presented as having a role to play in the reduction of bladder instability, while a new formulation of oxybutinin was shown to improve female
urge incontinence. The combination of topical
estrogen and an oral agonist,
phenylpropanolamine, also gave significant improvement in menopausal urinary urgency and incontinence. Tetrahydropyranyladriamycin (THPA) will possibly be effective for adequate prophylaxis against the recurrence of early
bladder cancer. COX-2 receptor modulation has a role in the treatment of
bladder cancer, whilst the
endothelin receptor antagonist ABT-627 (Abbott International Ltd) may prove effective in the treatment of
prostate cancer.
Melanotan II (PNU-83757; Pharmacia and Upjohn Inc) and
IC-351 (Icos Corp) are new compounds for the treatment of
erectile dysfunction (ED), and more light is shed on a role for
apomorphine for the same indication.